Burlingame, CA – According to filings with the U.S. Securities and Exchange Commission, Humanigen Inc. is raising $5,000,000.00 in a new round of investment. Sources indicate as part of senior management Chief Financial Officer, Greg Jester played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Humanigen Inc.

Humanigen, Inc. is a biopharmaceutical company developing its Humaneered proprietary monoclonal antibodies to address critical unmet needs in today’s most advanced cancer therapies. Humaneering is a patented proprietary technology for converting suboptimal antibodies into human antibodies suitable for chronic therapies, in part, because of low immunogenicity. In completed clinical studies, the Humaneered antibodies showed lower immunogenicity than is generally seen with competing human antibody approaches. This platform has the advantage of maintaining epitope specificity and increasing affinity. To learn more about Humanigen Inc., visit http://www.humanigen.com/

Contact:
Greg Jester, Chief Financial Officer
650-243-3100
jester@humanigen.com
https://www.linkedin.com/in/greg-jester-493488a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved